Mir-206 functions as a tumor suppressor and directly targets K-Ras in human oral squamous cell carcinoma

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 1583-1591

  Lin, Feiou ^a   Yao, Linjie ^b   Xiao, Jin ^b   Liu, Dengfeng ^b   Ni, Zhenyu ^a  

^a Department of Orthodontics ^*  (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Invasion; MiR 206; Oral squamous cell carcinoma; Prognosis; Proliferation

Indexed keywords

K RAS PROTEIN; MICRORNA; MICRORNA 206; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; APOPTOSIS; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; ONCOGENE K RAS; OVERALL SURVIVAL; PROTEIN TARGETING; UPREGULATION;

EID: 84907219702     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S67624     Document Type: Article

References (40)

1. Sharma P, Saxena S, Aggarwal P. Trends in the epidemiology of oral squamous cell carcinoma in Western UP: an institutional study. Indian J Dent Res. 2010;21(3):316–319.
2. Massano J, Regateiro FS, Januario G, Ferreira A. Oral squamous cell carcinoma: review of prognostic and predictive factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102(1):67–76.
3. Rodrigo JP, Lequerica-Fernandez P, Rosado P, Allonca E, Garcia-Pedrero JM, de Vicente JC. Clinical significance of annexin A2 downregulation in oral squamous cell carcinoma. Head Neck. 2011;33(12):1708–1714.
4. Lin YT, Chuang HC, Chen CH, et al. Clinical significance of eryth-ropoietin receptor expression in oral squamous cell carcinoma. BMC Cancer. 2012;12:194.
5. Osman A. MicroRNAs in health and disease – basic science and clinical applications. Clin Lab. 2012;58(5–6):393–402.
6. Bartel D P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297.
7. Zhang B, Pan X, Cobb G P, Anderson TA. MicroRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1–12.
8. Dieckmann K P, Spiekermann M, Balks T, et al. MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours. Br J Cancer. 2012;107(10):1754–1760.
9. Takahashi M, Cuatrecasas M, Balaguer F, et al. The clinical significance of miR-148a as a predictive biomarker in patients with advanced colorectal cancer. PLoS One. 2012;7(10):e46684.
10. Iorio M V, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16): 7065–7070.
11. Wang X, Ling C, Bai Y, Zhao J. MicroRNA-206 is associated with invasion and metastasis of lung cancer. Anat Rec (Hoboken). 2011;294(1): 88–92.
12. Zhang L, Liu X, Jin H, et al. MiR-206 inhibits gastric cancer proliferation in part by repressing cyclinD2. Cancer Lett. 2013;332(1): 94–101.
13. Parasramka MA, Dashwood WM, Wang R, et al. A role for low-abundance miRNAs in colon cancer: the miR-206/Kruppel-like factor 4 (KLF4) axis. Clin Epigenetics. 2012;4(1):16.
14. Zhou L, Chen J, Li Z, et al. Integrated profiling of microRNAs and mRNAs: microRNAs located on Xq27.3 associate with clear cell renal cell carcinoma. PLoS One. 2010;5(12):e15224.
15. Chen X, Ya n Q, Li S, et al. Expression of the tumor suppressor miR-206 is associated with cellular proliferative inhibition and impairs invasion in ERα-positive endometrioid adenocarcinoma. Cancer Lett. 2012;314(1):41–53.
16. Wang R, Hu Y, Song G, et al. MiR-206 regulates neural cells proliferation and apoptosis via Otx2. Cell Physiol Biochem. 2012;29(3–4):381–390.
17. Missiaglia E, Shepherd CJ, Patel S, et al. MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas. Br J Cancer. 2010;102(12):1769–1777.
18. Bao Y P, Yi Y, Peng LL, et al. Roles of microRNA-206 in osteo-sarcoma pathogenesis and progression. Asian Pac J Cancer Prev. 2013;14(6):3751–3755.
19. Yang Q, Zhang C, Huang B, et al. Downregulation of microRNA-206 is a potent prognostic marker for patients with gastric cancer. Eur J Gastroenterol Hepatol. 2013;25(8):953–957.
20. Vickers MM, Bar J, Gorn-Hondermann I, et al. Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease. Clin Exp Metastasis. 2012;29(2): 123–132.
21. Shih C, Weinberg RA. Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell. 1982;29(1):161–169.
22. Caulin C, Nguyen T, Longley MA, Zhou Z, Wang XJ, Roop DR. Inducible activation of oncogenic K-ras results in tumor formation in the oral cavity. Cancer Res. 2004;64(15):5054–5058.
23. Funato T, Ishii T, Kambe M, Scanlon KJ, Sasaki T. Anti-K-ras ribozyme induces growth inhibition and increased chemosensitivity in human colon cancer cells. Cancer Gene Ther. 2000;7(3):495–500.
24. Fleming JB, Shen GL, Holloway SE, Davis M, Brekken RA. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justifcation for K-ras-directed therapy. Mol Cancer Res. 2005;3(7):413–423.
25. Shin KH, Bae SD, Hong HS, Kim RH, Kang MK, Park NH. MiR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras. Biochem Biophys Res Commun. 2011;404(4):896–902.
26. Yu S, Lu Z, Liu C, et al. MiRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res. 2010;70(14):6015–6025.
27. Chen X, Guo X, Zhang H, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene. 2009;28(10):1385–1392.
28. Zhao WG, Yu SN, Lu ZH, Ma YH, Gu YM, Chen J. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. Carcinogenesis. 2010;31(10):1726–1733.
29. Leivonen SK, Makela R, Ostling P, et al. Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene. 2009;28(44):3926–3936.
30. Taulli R, Bersani F, Foglizzo V, et al. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotrans-planted mice by promoting myogenic differentiation. J Clin Invest. 2009;119(8):2366–2378.
31. Liu GF, Tang D, Li P, et al. S-1-based combination therapy vs S-1 monotherapy in advanced gastric cancer: a meta-analysis. World J Gastroenterol. 2014;20(1):310–318.
32. Dey BK, Gagan J, Dutta A. MiR-206 and -486 induce myoblast differentiation by downregulating Pax7. Mol Cell Biol. 2011;31(1):203–214.
33. Song G, Zhang Y, Wang L. MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. J Biol Chem. 2009;284(46):31921–31927.
34. Kondo N, Toyama T, Sugiura H, Fujii Y, Yamashita H. MiR-206 expression is down-regulated in estrogen receptor α-positive human breast cancer. Cancer Res. 2008;68(13):5004–5008.
35. Zhang T, Liu M, Wang C, Lin C, Sun Y, Jin D. Down-regulation of miR-206 promotes proliferation and invasion of laryngeal cancer by regulating VEGF expression. Anticancer Res. 2011;31(11):3859–3863.
36. Tsang WP, Kwok TT. The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis. 2009;30(6):953–959.
37. Brennecke J, Stark A, Russell RB, Cohen SM. Principles of microRNA-target recognition. PLoS Biol. 2005;3(3):e85.
38. Krek A, Grun D, Poy MN, et al. Combinatorial microRNA target predictions. Nat Genet. 2005;37(5):495–500.
39. Margaritescu C, Pirici D, Simionescu C, et al. VEGF and VEGFRs expression in oral squamous cell carcinoma. Rom J Morphol Embryol. 2009;50(4):527–548.
40. Zhang T, Liu H, Liang Y, et al. The expression and significance of the Notch signaling pathway molecules in tongue squamous cell carcinoma. Hua Xi Kou Qiang Yi Xue Za Zhi. 2013;31(3):303–309. Chinese.